Related Experiment Videos
Arrhythmic risk stratification of post-myocardial infarction patients
F Naccarella1, G Lepera, A Rolli
1Dipartimento di Cardiologia, Azienda Sanitaria della Cittá di Bologna, Italy. wnacca@tin.it
Insights
Accurate risk stratification after myocardial infarction (MI) remains challenging. Combining noninvasive methods with electrophysiology studies offers a more reliable approach to identifying patients at high risk for arrhythmias post-MI.
Area of Science:
- Cardiology
- Electrophysiology
- Clinical Risk Stratification
Background:
- Post-myocardial infarction (MI) arrhythmic risk stratification is not fully resolved.
- Traditional methods using premature ventricular contractions and ejection fraction have limitations, as shown by CAST I/II trials.
- Amiodarone and beta-blockers show efficacy in specific post-MI patient groups, but risk stratification remains crucial.
Purpose of the Study:
- To review current methodologies for arrhythmic risk stratification in post-myocardial infarction patients.
- To evaluate the limitations of existing noninvasive and electrophysiological techniques.
- To highlight the most effective combined approach for identifying high-risk individuals.
Main Methods:
- Review of clinical trials and studies on post-MI risk stratification.
- Evaluation of noninvasive parameters: premature ventricular contractions, Holter monitoring, signal-averaged electrocardiography, heart rate variability, T-wave alternance.
- Assessment of electrophysiologic study (EPS) findings, particularly inducibility of ventricular tachycardia.
- Analysis of data from trials like CAST I/II, EMIAT, CAMIAT, and MADIT.
Main Results:
- Traditional methods (PVCs, EF) are limited and sometimes fallacious.
- Amiodarone demonstrated benefit in reducing arrhythmic mortality in selected post-MI patients (EMIAT, CAMIAT).
- Beta-blockers are effective in preventing sudden death post-MI.
- Electrophysiology study (EPS) shows high specificity for arrhythmic events, especially in patients with reduced ejection fraction (<35%) within 6 months post-MI.
- Noninvasive parameters like heart rate variability and signal-averaged ECG have low specificity.
Conclusions:
- A combined approach integrating noninvasive risk stratification (e.g., PVCs > 10/h, low heart rate variability, positive signal-averaged ECG) with electrophysiology study is the most convincing strategy.
- This combined method improves the identification of post-MI patients at high risk for arrhythmic events.
- Further research and trials are ongoing to refine these risk stratification techniques.
Abstract:
Post-myocardial infarction risk stratification, especially arrhythmic risk stratification, is an issue that has still not been wholly addressed in modern clinical cardiology. In the past 10 years, arrhythmic risk stratification has been approached mainly by evaluating frequency and complexity of premature ventricular contractions, detected on Holter monitoring, often in association with determination of percent ejection fraction. This methodology has been proven to be limited and fallacious according to the Cardiac Arrhythmia Suppression Trial I and II (CAST I,II) results, in which suppression of premature ventricular contractions or premature ventricular beats throughout by antiarrhythmic drugs resulted in an increase in both cardiac and arrhythmic mortality. Only amiodarone as an antiarrhythmic drug, as proven in the recent European Myocardial Infarct Amiodarone Trial (EMIAT) and Canadian Amiodarone Myocardial Infarction Trial (CAMIAT), was effective in reducing arrhythmic mortality without affecting cardiac mortality, in patients selected mainly because of a reduced ejection fraction, with and without premature ventricular contractions. Conversely, it is well known that beta-blockers are effective in preventing sudden death in post-acute myocardial infarction (AMI) patients, thus reducing cardiac and arrhythmic mortality. Conversely, in other institutions, risk stratification in post-AMI patients has been performed by electrophysiologic study obtained, without any previous noninvasive arrhythmic risk stratification, in all post-AMI patients. In recent years, many other noninvasive electrocardiology parameters, such as late potentials (signal-averaged electrocardiography), heart rate variability, baroreflex sensitivity, and, more recently, T-wave alternance, have been shown to be useful, but they are associated with a low specificity in the noninvasive identification of patients at high risk for arrhythmic mortality. Conversely, in the Multicenter Automatic Defibrillation Implantation Trial (MADIT), electrophysiology confirmed that inducibility of ventricular tachycardia shows high specificity and a high predictive value for arrhythmic events. Nevertheless, the MADIT study population is not comparable to a cohort of consecutive patients who have recently had a myocardial infarction. In this setting, the highest risk of arrhythmic events can be observed in patients with depressed percent ejection fraction (< 35%) and in the first 6 months after AMI. Today, the most convincing approach seems to be the one combining both noninvasive risk stratification parameters (e.g., premature ventricular beats > 10/h or reduced heart rate variability < 70 ms or a positive signal-averaged electrocardiogram) followed by a further arrhythmic risk stratification, obtained through electrophysiologic study. Several published and ongoing trials that utilize various arrhythmic risk stratification techniques as part of their protocol are reviewed.